These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 24612167

  • 1. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
    Groop PH, Del Prato S, Taskinen MR, Owens DR, Gong Y, Crowe S, Patel S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2014 Jun; 16(6):560-8. PubMed ID: 24612167
    [Abstract] [Full Text] [Related]

  • 2. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, Hehnke U, Woerle HJ, von Eynatten M.
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
    Thrasher J, Kountz DS, Crowe S, Woerle HJ, von Eynatten M.
    Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.
    Zeng Z, Choi DS, Mohan V, Emser A, Siddiqui K, Gong Y, Patel S, Woerle HJ.
    Curr Med Res Opin; 2015 Jan; 31(1):99-106. PubMed ID: 25215428
    [Abstract] [Full Text] [Related]

  • 5. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus.
    Nauck M, Araki A, Hehnke U, Plat A, Clark D, Khunti K.
    Int J Clin Pract; 2018 Oct; 72(10):e13240. PubMed ID: 30216648
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.
    von Eynatten M, Gong Y, Emser A, Woerle HJ.
    Cardiovasc Diabetol; 2013 Apr 09; 12():60. PubMed ID: 23570327
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.
    Hong JH, Kim MJ, Min KW, Won JC, Kim TN, Lee BW, Kang JG, Kim JH, Park JH, Ku BJ, Lee CB, Kim SY, Shon HS, Lee WJ, Park JY.
    Diabetes Obes Metab; 2025 Jan 09; 27(1):81-91. PubMed ID: 39375869
    [Abstract] [Full Text] [Related]

  • 8. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
    Schernthaner G, Barnett AH, Emser A, Patel S, Troost J, Woerle HJ, von Eynatten M.
    Diabetes Obes Metab; 2012 May 09; 14(5):470-8. PubMed ID: 22268497
    [Abstract] [Full Text] [Related]

  • 9. The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.
    Elbarbary NS, Ismail EA, El-Hamamsy MH, Ibrahim MZ, Elkholy AA.
    Diabetologia; 2024 Dec 09; 67(12):2637-2649. PubMed ID: 39271520
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE.
    J Bone Miner Res; 2005 Dec 09; 20(12):2105-15. PubMed ID: 16294264
    [Abstract] [Full Text] [Related]

  • 11. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH.
    Cochrane Database Syst Rev; 2015 Oct 26; 2015(10):CD007698. PubMed ID: 26497719
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials.
    Lyu YS, Hong S, Lee SE, Cho BY, Park CY.
    Cardiovasc Diabetol; 2024 Feb 15; 23(1):71. PubMed ID: 38360626
    [Abstract] [Full Text] [Related]

  • 13. Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.
    Asgharzadeh A, Patel M, Connock M, Damery S, Ghosh I, Jordan M, Freeman K, Brown A, Court R, Baldwin S, Ogunlayi F, Stinton C, Cummins E, Al-Khudairy L.
    Health Technol Assess; 2024 Dec 15; 28(80):1-190. PubMed ID: 39673446
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A, Wyndaele JJ, Sieber P.
    Am J Geriatr Pharmacother; 2006 Mar 15; 4(1):14-24. PubMed ID: 16730617
    [Abstract] [Full Text] [Related]

  • 15. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.
    Chung S, Ben-Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, Hebert D, Isojärvi J, Doty P.
    CNS Drugs; 2010 Dec 15; 24(12):1041-54. PubMed ID: 21090838
    [Abstract] [Full Text] [Related]

  • 16. Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
    Cooper TE, Khalid R, Chan S, Craig JC, Hawley CM, Howell M, Johnson DW, Jaure A, Teixeira-Pinto A, Wong G.
    Cochrane Database Syst Rev; 2023 Oct 23; 10(10):CD013631. PubMed ID: 37870148
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Education programmes for people with chronic kidney disease and diabetes.
    Cashmore BA, Cooper TE, Evangelidis NM, Green SC, Lopez-Vargas P, Tunnicliffe DJ.
    Cochrane Database Syst Rev; 2024 Aug 22; 8(8):CD007374. PubMed ID: 39171639
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.
    Lim AWY, Schneider L, Loy C.
    Cochrane Database Syst Rev; 2024 Nov 05; 11(11):CD001747. PubMed ID: 39498781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.